菏泽医治{风湿}费用(烟台山东治风湿好的医院是哪家) (今日更新中)

ISLAMABAD, Nov. 14 (Xinhua) -- Pakistan ranks the seventh in the world in terms of diabetes prevalence rate and over 7.1 million people in the country are diabetes patients, reported local media on Monday.Quoting a report by the World International Diabetes Federation, a local English newspaper "The News" said that every year 89,000 people die of diabetes in Pakistan and the number of diabetes patients in the country could hit 11.5 million by the year 2025 if proper measures were not taken.This would make Pakistan the world's fifth largest country in terms of its number of diabetes patients 14 years later, warned the report.At a seminar organized Monday in Islamabad to observe the World Diabetes Day which falls on Nov. 14, Dr. Abdus Salam from Shifa International Hospital, a private-run hospital in the capital city, said that every ten seconds, two people are diagnosed with diabetes and one person dies of diabetes-related causes.The average age of diabetes patients in Pakistan is one of the lowest in the world, said the report. In a bid to raise public awareness about the harmful effects of diabetes, various diabetes camps, scientific sessions, seminars and walks were organized across the country on Monday to mark the World Diabetes Day.In a message delivered on Sunday, Pakistani Prime Minister Yusuf Raza Gilani said that the World Diabetes Day draws attention to the lethality of the disease and underscores the need of preventive measures at individual and collective levels."Diabetes is a killer which is taking the life of one person out of every 800," said the prime minister, adding that "this disease hits people of all age groups, rich and poor alike without any discrimination."

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

SAN FRANCISCO, Nov. 17 (Xinhua) -- Online retail giant Amazon is working on a smartphone scheduled to be released in the fourth quarter of 2012, U.S. media reported Thursday.A note from Citigroup analyst Mark Mahaney obtained by technology news site All Things Digital said that based on the supply chain checks in Asia, Amazon is believed to launch a smartphone in the fourth quarter of 2012.According to the note, Amazon is working with manufacturer Foxconn and the device will run Texas Instruments' OMAP 4 processor. The Kindle Fire, the latest tablet introduced by the e- commerce giant, also uses OMAP processor.The analyst said the smartphone will cost Amazon between 150 and 170 U.S. dollars to build and the company could sell the handset at or near its cost rather than a 30 percent gross margin like many other smartphone manufacturers usually do.The move is expected to further intensify Amazon's rivalry with Apple and Google after the e-commerce giant had made moves on some booming businesses like tablet computer and cloud-computing service.

BEIJING, Nov. 16 (Xinhua) -- A senior Chinese commerce official said on Wednesday that the country will work to optimize the import mix of mechanical and electronic products so they can play a bigger role in China's restructuring efforts.Li Jinzao, vice minister of the Ministry of Commerce, made the remarks at a forum of the ongoing 13th "China Hi-Tech Fair" in Shenzhen.His remarks echoed a guideline issued in March on promoting the imports of mechanical and electronic products during the 2011-2015 period, in which China pledged efforts to encourage the imports of high-tech products.Li said that China will improve existing policies to attach more importance to the imports of advanced technology, equipment and components to spur innovation.Meanwhile, he said China will organize more trading events to exchange and cooperate with international businesses, and will continue to push the United States and European countries to ease restrictions on civil high-tech exports to China.

BEIJING, Oct. 11 (Xinhuanet) -- Debates in the medical field developed on Monday as a U.S. government panel recommended that men of all ages should stop getting prostate cancer blood screenings.The United States Preventive Services examined all the evidence and found little if any reduction in deaths from routine P.S.A. screening and suggested that the test does more harm than good to healthy men.The P.S.A. test for prostate cancer, a blood test to screen for a protein that may indicate cancer, has become widely used because it can help detect tiny tumors at a very early sta ge, when they are theoretically most treatable.Unfortunately, according to the task force, the vast majority of the results are false-positives: the men don’t actually have cancer. And most of those found to have cancerous cells would not suffer ill effects because their cancer is so slow-growing that it would not cut short their lives. Those with faster-growing cancers may also not be helped if the cancer is extremely aggressive.After the recommendation came out last week, many prostate cancer specialists have been pushing back.Urologist Dr. Mark DeGuenther said this recommendation is more about saving money than saving lives. He said death rates from prostate cancer have dropped 40 percent since men began getting screened at age 40 and he says it will save taxpayers and patients more money in the long run to diagnose and treat cancers earlier rather than wait and have to provide expensive care for advanced stage cancers."We all agree that we've got to do a better job of figuring out who would benefit from P.S.A. screening," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago. "But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible."Dr. Deepak Kapoor, chairman and chief executive of Integrated Medical Professionals, which includes the nation's largest urology practice, said "We will not allow patients to die, which is what will happen if this recommendation is accepted."That task force's recommendation isn't final - it's a draft open for public debate. And obviously the debate is already under way.

来源：资阳报